Search

 
Start a new search




Results 1-10 of 11.
 |   | 
JRC N°Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)
JRC1042782017Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-VersagenAUTENRIETH M.; HORN Thomas; KURTZ F; NGUYEN K; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SCHWAIGER M.; BLECHERT B.; SEIDL C.; SENEKOWITSCH-SCHMIDTKE R.; GSCHWEND J.e.; SCHEIDHAUER Klemens
JRC952242015Fractionated intravesical radioimmunotherapy with 213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinomaFAZEL J; RÖTZER S; SEIDL C.; FEUERECKER Benedikt; AUTENRIETH Michael; WEIRICH G; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.
JRC886702014Treatment of bladder cancer with Bi-213-anti-EGFR-MAb – a pilot studySCHEIDHAUER Klemens; SEIDL C.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; AUTENRIETH Michael; KURTZ F; ESSLER M.; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.
JRC737802013Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenationWULBRAND Christian; SEIDL C.; GAERTNER F. C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; ESSLER M.; SENEKOWITSCH-SCHMIDTKE R.
JRC795752013Treatment of Bladder Cancer with Bi-213-anti-EGFR Immunoconjugates in a Nude Mouse ModelSEIDL C.; PFOST B.; MÜLLER Felix; RÖTZER S; FAZEL J; GILBERTZ K.-P.; FEUCHTINGER A; WEIRICH G; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; AUTENRIETH M.; ESSLER M.; SENEKOWITSCH-SCHMIDTKE R.
JRC765832012Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrestVALLON M.; SEIDL C.; BLECHERT B.; LI Zhoulei; GILBERTZ K.-P.; BAUMGART Anja; AICHLER M; FEUCHTINGER A; GAERTNER F. C.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; WALCH Axel K.; SENEKOWITSCH-SCHMIDTKE R.; ESSLER M.
JRC702982012Die intravesikale Radioimmuntherapie mit Bi-213-anti-EGFR Immunkonjugaten verursacht keine Schäden am UrothelMÜLLER Felix; SEIDL C.; WEIRICH G; RÖTZER S; FAZEL J; FRANK Annette; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SENEKOWITSCH-SCHMIDTKE R.
JRC648812012High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneumRAUCH C; SEIDL C.; SCHLAPSCHY M; SKERRA A; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; SENEKOWITSCH-SCHMIDTKE R.
JRC680422012Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosisESSLER M.; GAERTNER F. C.; NEFF Frauke; BLECHERT B.; SENEKOWITSCH-SCHMIDTKE R.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; SEIDL C.
JRC655312011177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213BiSEIDL C.; ZÖCKLER C; BECK R.; QUINTANILLA-MARTINEZ L; BRUCHERTSEIFER Frank; SENEKOWITSCH-SCHMIDTKE R.
Results 1-10 of 11.

Discover